申请人:PHARMA MAR SAU
公开号:WO2004011458A1
公开(公告)日:2004-02-05
Compounds of the general formula (I) or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR'3, SOR', SO2X, C(=0)R', C(=O)OR', C(=O)NR', substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R' is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R' is selected from the group consisting of H, OH, OR', OCOR', SH, SR', SOR', S02R', N02, NH2, NHR', N(R')2, NHCOR', N(COR')2, NHS02R', CN, halogen, C(=0)H, C(=0)R', C02H, C02R', CH20R, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; with the proviso that the compound is not compound 1, 3 or 4 of US 5,514,708. The compounds have antitumour activity. A synthetic route is also provided.
提供通式(I)或其药学上可接受的盐、衍生物、前药或立体异构体:其中由R定义的取代基团分别独立地选自包括H、SiR'3、SOR'、SO2X、C(=0)R'、C(=O)OR'、C(=O)NR'、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、芳基、杂环芳基或芳基烷基的群;R'组选自取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、氨基烷基、芳基、芳基烷基和杂环族;R'组选自H、OH、OR'、OCOR'、SH、SR'、SOR'、S02R'、N02、NH2、NHR'、N(R')2、NHCOR'、N(COR')2、NHS02R'、CN、卤素、C(=0)H、C(=0)R'、C02H、C02R'、CH20R、取代或未取代的烷基、取代或未取代的卤代烷基、取代或未取代的烯基、取代或未取代的烷基亚烯、取代或未取代的炔基、取代或未取代的芳基、取代或未取代的芳基烷基和取代或未取代的杂芳基;但该化合物不是美国专利5,514,708的化合物1、3或4。这些化合物具有抗肿瘤活性。同时提供了一种合成路线。